Outline / History

OUTLINE

Name	Teijin Meguro Institute Co., Ltd.
Head Office	6-4, Fushimi-machi 2-chome Chuo-ku, Osaka 541-0044, Japan Telephone(06)6223-1451 Facsimile(06)6223-1453
Kasai Factory	318-1, Aza Kotaninoue-Otsu, Hanjo-cho, Kasai-city, Hyogo 675-2101, Japan Telephone(0790)49-2361 Facsimile(0790)49-1329
Foundation	May 1925
Capital	￥35,200,000
President	Takanori Miyoshi
Line of work	Manufacturer,sales, and export of medical drugs, diagnostic, food supplement, and feed additives.

HISTORY

Meguro Institute Co., Ltd was established by the late Dr. Yozaburo Meguro who graduated from Osaka prefectural medical school in 1910. Then he studied under Dr. Kiyoshi Shiga of “National Institute of Infectious Diseases” regarding bacteriology and immunology. After that, Dr. Meguro devoted himself to medical study for 4 years with Dr. Kiyoshi Shiga at the Kitasato Institute, established by Dr. Shibasaburo Kitasato.
Then Dr. Meguro went to Europe to study abroad, he studied under Dr. Bordet of Institut Pasteur in Belgium, and Dr. Ramone of Institut Pasteur in France, respectively.

1925	Osaka Experimental Therapy Institute (Kita-ku, Osaka-shi) was founded.
1929	Launched “Biogenin”, preparation of Lactic acid bacteria.
1931	Launched “Diphtherial Formo-vaccine”.
1937	The company name was altered to Meguro Institute from Osaka Experimental Therapy Institute. Launched “Diphtherial Serum”.
1945	The facilities of Meguro Institute in Osaka were burnt down by war. Then the institute was relocated to Kohda-cho, Ikeda-shi, Osaka.
1948	Constructed new facilities at Masumi-cho, Ikeda-shi. Simultaneously, the company organization was converted to joint-stock corporation, and the company name was revised to Meguro Institute Co., Ltd.
1950	Launched “Typhus Vaccine”.
1952	Resumed the sale of “Biogenin”.
1958	Launched “Japanese encephalitis Vaccine”.
1968	Launched “Conc-Enteropoly-R”, preparation of multidrug-resistant Lactic Acid Bacteria, and “Bionattomin”, preparation of Bacillus subtilis (natto) BN. Both preparations were supplied to the manufacturers of gastrointestinal drugs as the raw materials.
1977	Launched “Reversecell”, diagnostic kit for detection of HBs Ag in serum.
1980	Kasai Factory complying with GMP was newly established in Kasai-shi, Hyogo-Prefecture. The capacity for production of probiotic preparations and organ extracts (discontinued in later years) was extended.
1997	Turned into a subsidiary of Maruishi Pharmaceutical Co., Ltd.
2003	Expansion of Kasai Factory was completed.
2014	Construction of the new plant was completed in Kasai factory. Ikeda factory was closed and integrated into Kasai factory. The head office was relocated to Chuo-ku, Osaka.